Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 26.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 26.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Athenex, Daiichi Sankyo Inc., Genentech, Genomic Health, Lilly, MacroGenics Inc., Merck & Co Inc., Novartis Pharmaceuticals Corporation, and Pfizer.

For further information concerning Lilly grant funding, visit

School of Breast Oncology® Online Curriculum

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Repurposing Statement

If you previously attended and received credit for the live CME-/CE-certified conference, 17th Annual School of Breast Oncology®, which was held from October 31 to November 2, 2019, in Atlanta, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will Physicians’ Education Resource®, LLC (PER®), award, duplicate credit for the activity.

Activity Overview

An increasing number of oncologists are focusing their clinical practices on the treatment of breast cancer, creating a need for specialized education. The School of Breast Oncology®, which has been held annually since 2003, was developed to advance patient care by providing a curriculum-based program focused exclusively on breast cancer clinical management. This intensive 3-day interactive program provides a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment, with lectures emphasizing the clinical implications presented by leading clinical investigators. The School of Breast Oncology® both provides a comprehensive overview for fellows or oncologists who are new to practice and serves as a valuable refresher course, with updates on the latest data and changes to standards of care for oncologists who have been in practice for several years or more. This online activity captures all of the lectures presented at the live 2019 School of Breast Oncology®, organizes them in a convenient modular format, and summarizes the existing data for each topic, with an emphasis on the evidence-based foundations for optimal, individualized decision making in the clinic.

Benefits of Participating

  • Gain insights into using biologic subtype as well as predictive and prognostic biomarkers for treatment selection
  • Recognize factors that increase the risk of breast cancer development and adopt strategies for risk reduction in high-risk women
  • Learn to utilize and interpret results from breast imaging modalities
  • Review the latest innovations in locoregional control, including surgical and radiation advances
  • Outline tactics for individualizing (neo)adjuvant therapy for early-stage and locally advanced breast cancers based on breast cancer subtype and recurrence risk
  • Integrate novel agents into treatment algorithms for metastatic disease based on expert guidelines and emerging clinical evidence
  • Improve recognition and management of adverse events associated with newer treatment options
  • Apply the latest evidence, therapies, and strategies in your breast cancer practice

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Athenex, Daiichi Sankyo Inc., Genentech, Genomic Health, Lilly, MacroGenics Inc., Merck & Co Inc., Novartis Pharmaceuticals Corporation, and Pfizer.

For further information concerning Lilly grant funding, visit

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of breast cancer.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review breast cancer biology, molecular subtyping, staging, and prognostic and/or predictive biomarkers, in order to better individualize therapy and counsel patients regarding conventional and investigational treatment options
  • Integrate genomic and molecular biomarkers, and gene expression assays, into treatment planning to optimize outcomes for patients with breast cancer
  • Discuss the application of current and evolving imaging options for diagnosing, staging, and monitoring breast cancer
  • Incorporate current guidelines and evolving evidence with regard to local treatment options, including advances in surgery and radiation therapy, into the management of patients with breast cancer
  • Individualize selection of systemic therapies for patients with early-stage or advanced/metastatic breast cancer by taking into consideration efficacy and safety data, expert guidelines, patient characteristics and co-morbidities, and genomic and/or molecular tumor information
  • Evaluate emerging clinical data and evolving strategies for the treatment of breast cancer, and apply clinical trial data appropriately in order to optimize outcomes for individual patients
  • Utilize supportive care strategies for preventing and managing treatment-related adverse events in patients receiving therapy for breast cancer
  • Facilitate awareness of clinical trial opportunities based on knowledge of emerging approaches and variances in care in the field of breast cancer management

Faculty, Staff, and Planners’ Disclosures


Joyce O’Shaughnessy
Joyce O’Shaughnessy, MD
Celebrating Woman Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Disclosures: Consultant: AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol- Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Seattle Genetics, Syndax Pharmaceuticals, Takeda.

Carey K. Anders
Carey K. Anders, MD
Associate Professor of Medicine
Division of Hematology Oncology
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Disclosures: Grant Research Support: PUMA, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1 Therapeutics; Consultant: PUMA, Genentech, Eisai, IPSEN; Other: Royalties: Up to date, Jones and Bartlett.

Douglas W. Arthur
Douglas W. Arthur, MD, FABS, FASTRO
Professor and Chairman
Florence and Hyman Meyers Chair
Department of Radiation Oncology
Virginia Commonwealth University School of Medicine
Massey Cancer Center
Richmond, VA

Disclosures: Other: Advanced Radiation Therapy - scientific advisor.

Timothy D’Alfonso
Timothy D’Alfonso, MD
Associate Attending
Department of Pathology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: PAIGE.AI.

David M. Euhus
David M. Euhus, MD, FACS
Professor (PAR) of Surgery
Chief, Breast Surgery Section
Division of Surgical Oncology
John Hopkins Medicine
Baltimore, MD

Disclosures: no relevant financial relationships with commercial interest.

Carol Fabian
Carol Fabian, MD
University Distinguished Professor
Mark and Bette Morris Family Professorship in Cancer Prevention
Director, Breast Cancer Prevention and Survivorship Research Center
The University of Kansas
Westwood, KS

Disclosures: Grant Research Support: No monetary grants other than Breast Cancer Research Foundation. Institution receives Duavee from Pfizer for a clinical prevention trial; Other: DSM provided study agent and placebo received for clinical trial.

Karin Hahn
Karin Hahn, MD, MSc, MPH, FRCPC
Chief, Division of Medical Oncology
London Health Sciences Center
Associate Professor
Schulich School of Medicine and Dentistry
Western University
Ontario, Canada

Disclosures: no relevant financial relationships with commercial interests.

Eleanor Harris
Eleanor Harris, MD
Vice-chair for Clinical Programs and Quality
Department of Radiation Oncology
Seidman Cancer Center University Hospitals
Clinical Professor
Case Western Reserve University Medical School
Cleveland, OH

Disclosures: no relevant financial relationships with commercial interests.

Kent K. Higdon
Kent K. Higdon, MD, FACS
Associate Professor
Program Director
Department of Plastic Surgery
Vanderbilt University Medical Center
Nashville, TN

Disclosures: no relevant financial relationships with commercial interests.

Claudine Isaacs
Claudine Isaacs, MD
Professor Co-Director, Breast Cancer Program
Medical Director, Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research Georgetown University
Washington, DC

Disclosures: Grant Research Support: Tesaro, Pfizer; Consultant: Pfizer, AstraZeneca, Genentech, Novartis, Context; Speakers Bureau: Genentech.

Henry M. Kuerer
Henry M. Kuerer, MD, PhD, FACS, CMQ
Executive Director, Breast Programs, MD Anderson Cancer Network
Robinson Endowed Distinguished Professor of Surgery and Cancer Research
Director, Breast Surgical Oncology Training Program The University of Texas MD Anderson Cancer
Center Houston, TX

Disclosures: Grant Research Support: National Cancer Institute; Consultant: Gerson Lehrman Group; Other: New England Journal of Medicine Group (associate editor), NRG Oncology (institutional PI and Breast Committee), American Society of Breast Surgeons (editor, Cancer management, breast education self-assessment program), chair Publications Committee).

Charles Loprinzi
Charles Loprinzi, MD
Regis Professor of Breast Cancer Research
Co-Director, Cancer Prevention and Control Program Mayo Clinic
Rochester, MN

Disclosures: Grant Research Support: Bristol-Myers Squibb, Pfizer; Consultant: PledPharma, Metys, Asahi Kasei Pharma, OnQuality Pharma.

Anne McTiernan
Anne McTiernan, MD, PhD
Member, Epidemiology
Fred Hutchinson Cancer Research Center
Full Professor (Research), Epidemiology and Geriatrics University of Washington Schools of Public
Health and Medicine Seattle, WA

Disclosures: Shareholder: Merck (husband).

Hyman Muss
Hyman Muss, MD
Mary Jones Hudson Distinguished Professor of Geriatric Oncology
Professor of Medicine
University of North Carolina at Chapel Hill Director of Geriatric Oncology
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Disclosures: no relevant financial relationships with commercial interests.

Ruth O’Regan
Ruth O’Regan, MD
Chief, Hematology and Medical Oncology Associate Director,
Clinical Research
University of Wisconsin Carbone Comprehensive Cancer Center
Madison, WI

Disclosures: Grant Research Support: Eisai, Pfizer, Novartis, Cascadian; Consultant: Pfizer, Genomic Health, Biotheranostics, Novartis, PUMA, Genentech, Immunomedics, MacroGenics

Andrew Poklepovic
Andrew Poklepovic, MD
Associate Professor Harrison Scholar
Hematology Oncology & Palliative Care
Medical Director, Dalton Outpatient Ambulatory Oncology Center Medical Director, Massey Cancer
Center Clinical Trials Office Virginia Commonwealth University Massey Cancer Center
Richmond, VA

Disclosures: Grant Research Support: Virginia Commonwealth Health Research Board; Consultant: Novartis; Speakers Bureau: Bristol-Myers Squibb; Other: Advisory Board: Merck, Castle Biosciences

Shannon R. Poppito
Shannon R. Poppito, PhD
Clinical Psychologist | Psycho-Oncologist Behavioral Health Oncology Consultant Behavioral Health
Oncology [BHOPE] Service Baylor University Medical Center
Charles A. Sammons Cancer Center
Dallas, TX

Disclosures: no relevant financial relationships with commercial interests.

Elizabeth Rafferty
Elizabeth Rafferty, MD
Director of Breast Imaging Programs Medical Director, Women’s Health Imaging L&M Radiology
Lawrence, MA

Disclosures: Grant Research Support: Hologic Inc, for investigation of tomosynthesis; Consultant: Hologic Inc.

David M. Schuster
David M. Schuster, MD, FACR
Professor, Department of Radiology and Imaging Sciences Director, Division of Nuclear Medicine and
Molecular Imaging Department of Radiology and Imaging Sciences
Emory University
Atlanta, GA

Disclosures: Grant Research Support: Blue Earth Diagnostics Ltd, Nihon Medi-Physics Co Ltd, Telix Pharmaceuticals (US) Inc, Advanced Accelerator Applications (through Emory Office of Sponsored Projects); Consultant: Syncona, AIM Specialty Health

Joseph A. Sparano
Joseph A. Sparano, MD
Professor, Department of Medicine (Oncology)
Professor, Department of Obstetrics, Gynecology, and Women’s Health
Associate Chairman for Clinical Research,
Department of Oncology Montefiore Medical Center
Associate Director for Clinical Research Albert Einstein Cancer Center
Bronx, NY

Disclosures: Grant Research Support: Deciphera, Prescient Therapeutics; Consultant: Astra Zeneca, Novartis, Pfizer, Genentech/Roche, Eli Lilly, Celgene, CStone, Cardinal Health; Shareholder: MetaStat

Sara M. Tolaney
Sara M. Tolaney, MD, MPH
Assistant Professor of Medicine,
Harvard Medical School Associate Director,
Susan F. Smith Center for Women’s Cancers Senior Physician
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant Research Support: Genentech, Lilly, Novartis, AstraZeneca, Merck, Pfizer, Nektar, Exelixi, Bristol-Myers Squibb, Eisai, Cyclacel, Immunomedics, Odonate; Consultant: Puma, Nektar, Merck, AstraZeneca, NanoString, Lilly, Pfizer, Novartis, Eisai, Genentech, Immunomedics, Sanofi, Celldex, Paxman, Seattle Genetics, Odonate, Bristol-Myers Squibb

Tiffany A. Traina
Tiffany A. Traina, MD
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center Associate Professor
Weill Cornell Medical College
New York, NY

Disclosures: Grant Research Support: Eisai, Pfizer, Novartis, Innocrin Pharma, AstraZeneca, Astellas Pharma, Immunomedics, Genentech/Roche, Daiichi Sankyo; Consultant: Genentech, Medivation, Pfizer, AstraZeneca, Merck, Astellas Pharma, Puma Biotechnology, Advaxis, Celgene, Innocrin Pharma, Genomic Health, Bristol-Myers Squibb, Samsung, Athenex, Aduro Biotech, Halozyme; Speakers Bureau: Roche/Genentech

Catherine Van Poznak
Catherine Van Poznak, MD, FASCO
Associate Professor
Division of Hematology Oncology Department of Internal Medicine
University of Michigan
Ann Arbor, MI

Disclosures: Grant Research Support: Bayer; Other: Novartis (uncompensated) phase IV study steering committee.

Jeffrey N. Weitzel
Jeffrey N. Weitzel, MD
Professor of Oncology and Population Sciences Director,
Division of Clinical Cancer Genomics
City of Hope Cancer Center
Duarte, CA

Disclosures: no relevant financial relationships with commercial interests.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By